BrainsWay Ltd. (TLV:BWAY)
2,900.00
+49.00 (1.72%)
Nov 3, 2025, 3:37 PM IDT
BrainsWay Revenue
BrainsWay had revenue of $12.63M USD in the quarter ending June 30, 2025, with 26.26% growth. This brings the company's revenue in the last twelve months to $46.08M, up 26.50% year-over-year. In the year 2024, BrainsWay had annual revenue of $41.02M with 29.04% growth.
Revenue (ttm)
$46.08M
Revenue Growth
+26.50%
P/S Ratio
6.98
Revenue / Employee
$384.03K
Employees
120
Market Cap
1.08B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.02M | 9.23M | 29.04% |
| Dec 31, 2023 | 31.79M | 4.61M | 16.96% |
| Dec 31, 2022 | 27.18M | -2.48M | -8.36% |
| Dec 31, 2021 | 29.66M | 7.60M | 34.46% |
| Dec 31, 2020 | 22.06M | -1.04M | -4.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 56.02B |
| Danel (Adir Yeoshua) | 2.84B |
| Novolog (Pharm-Up 1966) | 2.04B |
| Ilex Medical | 927.57M |
| Kamada | 571.15M |
| InterCure | 243.12M |
| SofWave Medical | 234.12M |
| Bait Bakfar | 106.25M |
BrainsWay News
- 6 days ago - BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025 - GlobeNewsWire
- 7 days ago - BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers - GlobeNewsWire
- 5 weeks ago - Do Options Traders Know Something About Brainsway Stock We Don't? - Nasdaq
- 6 weeks ago - BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care - Nasdaq
- 6 weeks ago - FDA Clearance Boosts BrainsWay (BWAY) Shares - GuruFocus
- 6 weeks ago - BrainsWay rises as FDA clears accelerated Deep TMS protocol - Seeking Alpha
- 6 weeks ago - BrainsWay (BWAY) Gains FDA Approval for Enhanced Depression Treatment Protocol - GuruFocus
- 2 months ago - BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. - GlobeNewsWire